Novartis cannot block generic of best-selling heart drug, US appeals court says
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto.
Why Novartis (NVS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast cancer; Study to start mid-2025. Data from ongoing phase 3 OPERA-01 study, using palazestrant alone as a monotherapy to target patients with ER+/HER2- metastatic breast cancer, expected in 2026. The global breast cancer market size is predicted to surpass $89.01 billion by 2034.
2 Dividend Stocks to Buy and Hold Forever
No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going and growing for as long as possible -- preferably forever.
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.
Novartis: launch of Morphosys drug by could be 2027 or later
Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data.
Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio
The pharma company raised its guidance on revenue growth from its key treatments and expected drug launches, and now anticipates annual currency-adjusted sales to grow by 6% through 2028.
Novartis raises annual sales guidance until 2028
Novartis on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions.
Here's Why Novartis (NVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
Novartis (NVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
